Theravance Biopharma, Inc. Deferred Tax Assets, Capital Loss Carryforwards
Theravance Biopharma, Inc. (TBPH) had Deferred Tax Assets, Capital Loss Carryforwards of $22.80 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2026-03-23
- 2025-12-31: Deferred Tax Assets, Capital Loss Carryforwards $22.80M.
- 2024-12-31: Deferred Tax Assets, Capital Loss Carryforwards $20.09M.
- 2023-12-31: Deferred Tax Assets, Capital Loss Carryforwards $21.48M.
- 2022-12-31: Deferred Tax Assets, Capital Loss Carryforwards $19.41M.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2025-12-31 | $22.80M 10-K · filed 2026-03-23 |
| 2024-12-31 | $20.09M 10-K · filed 2026-03-23 |
| 2023-12-31 | $21.48M 10-K · filed 2025-03-07 |
| 2022-12-31 | $19.41M 10-K · filed 2024-03-01 |
| 2021-12-31 | $19.41M 10-K · filed 2023-03-01 |
| 2020-12-31 | $19.41M 10-K · filed 2022-02-28 |
| 2019-12-31 | $19.41M 10-K · filed 2021-02-26 |
| 2018-12-31 | $19.41M 10-K · filed 2020-02-27 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |